Sam Banister
Co-founder & Chief Scientific Officer XYLO Therapeutics
Seminars
Wednesday 16th September 2026
Integrating AI to Advance 5 HT Receptor–Driven Neuroplasticity: Rewiring Neural Circuitry with Next Generation Computational Neurotherapeutics
2:15 pm
- How AI driven molecular design accelerates the development of selective 5 HT–modulating neuroplastogens now progressing into first in human evaluation
- Leveraging early PoC data, behavioral readouts, and advanced receptor profiling to refine mechanism driven therapeutic hypotheses
- Integrating computational chemistry, circuit level neuroscience, and PD biomarkers to optimise next generation non hallucinogenic neuroplastogens
- Translating scalable AI workflows into a diversified clinical pipeline spanning depression, pain, and substance use disorders
